首页> 外文期刊>Endocrine journal >Mortality in 154 surgically treated patients with acromegaly--a 10-year follow-up survey.
【24h】

Mortality in 154 surgically treated patients with acromegaly--a 10-year follow-up survey.

机译:154位接受肢端肥大症手术治疗的患者的死亡率-一项为期10年的随访调查。

获取原文
获取原文并翻译 | 示例
       

摘要

To determine the effects of surgery and adjuvant therapy on the mortality rate of Japanese patients with acromegaly, 154 surgically treated patients were followed until death or December 2000. Mean follow-up period was 10.0 +/- 6.5 (SD) years. Postoperative GH levels, mean values of GH levels measured in the first postoperative month, were <2.5 ng/mL in 73 (47.4%), 2.5-5.0 ng/mL in 50 (32.5%), and >5.0 ng/mL in 31 patients (20.1%). Three of 123 patients with postoperative GH levels <5.0 ng/mL underwent a second transsphenoidal surgery (TSS), the other 120 received no further treatment. Additional treatments, including second TSS, medical treatment, and gamma-knife irradiation for residual tumor, were administered to 25 of 31 patients whose postoperative GH was >5.0 ng/mL. Among the total 154 patients surveyed, 11 (7.1%) died during the follow-up period. The standard mortality ratio (SMR) was 1.17, not different from age- and sex-matched controls. The SMR of the 72 patients with postoperative GH <2.5 ng/mL was better than that of the 51 patients whose postoperative GH was 2.5-5.0 ng/mL (1.09 vs. 1.64); however, the difference was not statistically significant. In conclusion, TSS and adequate adjuvant treatment decreased the excess mortality rate of acromegalics to nearly the same level as that of the general Japanese population.
机译:为了确定手术和辅助疗法对日本肢端肥大症患者死亡率的影响,随访了154例接受手术治疗的患者,直至死亡或2000年12月。平均随访时间为10.0 +/- 6.5(SD)年。术后GH水平(术后第一个月测得的GH水平平均值)分别为<2.5 ng / mL(73(47.4%)),2.5-5.0 ng / mL(50(32.5%))和31(> 5.0 ng / mL)患者(20.1%)。 123例术后GH水平<5.0 ng / mL的患者中有3例接受了第二次经蝶窦手术(TSS),其他120例未接受进一步治疗。 31例术后GH> 5.0 ng / mL的患者中有25例接受了其他治疗,包括第二次TSS,药物治疗和伽玛刀辐照。在接受调查的154位患者中,有11位(7.1%)在随访期间死亡。标准死亡率(SMR)为1.17,与年龄和性别匹配的对照组没有差异。术后GH <2.5 ng / mL的72例患者的SMR优于术后GH为2.5-5.0 ng / mL的51例(1.09 vs. 1.64);但是,差异在统计上并不显着。总之,TSS和适当的辅助治疗使肢端肥大症的过高死亡率降低到与日本普通人群几乎相同的水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号